Targeting BRAFV600E in the treatment of CRC
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| Auteur principal: | |
|---|---|
| Autres auteurs: | |
| Format: | Thèse |
| Langue: | English |
| Publié: |
Brac University
2024
|
| Sujets: | |
| Accès en ligne: | http://hdl.handle.net/10361/23250 |
| id |
10361-23250 |
|---|---|
| record_format |
dspace |
| spelling |
10361-232502024-06-09T21:06:09Z Targeting BRAFV600E in the treatment of CRC Roja, Mashwiyat Samrin Kabir, Eva Rahman School of Pharmacy, Brac University BRAFV600E CRC Colorectal cancer Cancer Rectum--Cancer Colon (Anatomy)--Cancer Cancer--Treatment This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 27-34). The increasing prevalence of BRAFV600E mutated cancers has led to the search and development of targeted therapies against BRAF mutation. Multiple cancers, including colorectal cancer (CRC), have been linked to this mutation. While the currently available CRC drugs have shown initial promise, long-term use of these drugs could lead to the emergence of resistant CRC cells; therefore, drug repurposing provides a powerful strategy to increase the existing drug pool. This docking-based study’s aim was to find the possible compounds that could inhibit the BRAF protein and treat BRAFV600E mutated CRC. Three classes of drugs antihypertensive, anti-cholesterol and anti-diabetic drugs were explored. Molecular docking, followed by superimposition, analyzing protein-ligand interactions and comparison of their pharmacokinetic properties were done. The anti-hypertensive drug, Verapamil showed promising results as it demonstrated good binding affinity and interaction with the target protein. However, further in vitro studies and biological assays should be performed to elucidate Verapamil’s efficacy. Mashwiyat Samrin Roja B. Pharmacy 2024-06-09T06:02:36Z 2024-06-09T06:02:36Z ©2022 2023-10 Thesis ID: 19346046 http://hdl.handle.net/10361/23250 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 47 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
BRAFV600E CRC Colorectal cancer Cancer Rectum--Cancer Colon (Anatomy)--Cancer Cancer--Treatment |
| spellingShingle |
BRAFV600E CRC Colorectal cancer Cancer Rectum--Cancer Colon (Anatomy)--Cancer Cancer--Treatment Roja, Mashwiyat Samrin Targeting BRAFV600E in the treatment of CRC |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Kabir, Eva Rahman |
| author_facet |
Kabir, Eva Rahman Roja, Mashwiyat Samrin |
| format |
Thesis |
| author |
Roja, Mashwiyat Samrin |
| author_sort |
Roja, Mashwiyat Samrin |
| title |
Targeting BRAFV600E in the treatment of CRC |
| title_short |
Targeting BRAFV600E in the treatment of CRC |
| title_full |
Targeting BRAFV600E in the treatment of CRC |
| title_fullStr |
Targeting BRAFV600E in the treatment of CRC |
| title_full_unstemmed |
Targeting BRAFV600E in the treatment of CRC |
| title_sort |
targeting brafv600e in the treatment of crc |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23250 |
| work_keys_str_mv |
AT rojamashwiyatsamrin targetingbrafv600einthetreatmentofcrc |
| _version_ |
1814309666463678464 |